News
12 Health Care Stocks Moving In Friday's Intraday Session
22 Mar 24
Movers
Sangamo Therapeutics Announces Pricing Of $24M Registered Direct Offering
22 Mar 24
News, Offerings
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
19 Mar 24
Analyst Color, Biotech, Equities, News, Health Care, Price Target, Initiation, Analyst Ratings, Movers, Trading Ideas, General
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Raises Price Target to $5
19 Mar 24
News, Price Target, Reiteration, Analyst Ratings
RBC Capital Reiterates Sector Perform on Sangamo Therapeutics, Maintains $2 Price Target
14 Mar 24
News, Price Target, Reiteration, Analyst Ratings
4 Analysts Assess Sangamo Therapeutics: What You Need To Know
13 Mar 24
Analyst Ratings
HC Wainwright & Co. Maintains Buy on Sangamo Therapeutics, Maintains $3 Price Target
13 Mar 24
News, Price Target, Analyst Ratings
Sangamo Therapeutics Expects Total Operating Expenses In The Range Of ~$145M-$165M In 2024
13 Mar 24
News, Guidance
Sangamo Therapeutics Q4 EPS $(0.34) Misses $(0.26) Estimate, Sales $2.04M Miss $8.10M Estimate
13 Mar 24
Earnings, News
Earnings Scheduled For March 13, 2024
13 Mar 24
Earnings
12 Health Care Stocks Moving In Monday's Intraday Session
19 Feb 24
Movers
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $3 Price Target
12 Feb 24
News, Price Target, Reiteration, Analyst Ratings
12 Health Care Stocks Moving In Monday's Intraday Session
12 Feb 24
Movers
Sangamo Therapeutics Announces FDA Alignment On Abbreviated Pathway To Potential Approval And EMA Prime Eligibility For ST-920 In Fabry Disease
12 Feb 24
Biotech, News, FDA, General
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $3 Price Target
6 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Why Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
6 Feb 24
News, Pre-Market Outlook, Markets, Movers, Trading Ideas
Sangamo Therapeutics Reports Updated Preliminary Data From Phase 1/2 STAAR Clinical Study Evaluating Isaralgagene Civaparvovec, Or ST-920; Says Productive Discussions Are Continuing With FDA On Pathways To Registration
5 Feb 24
News
Sangamo Therapeutics Gets European Medicines Agency PRIME Designation For Isaralgagene Civaparvovec For Treatment Of Fabry Disease
5 Feb 24
Biotech, News, General
Deep Dive Into Sangamo Therapeutics Stock: Analyst Perspectives (4 Ratings)
19 Jan 24
Analyst Ratings
12 Health Care Stocks Moving In Friday's Pre-Market Session
19 Jan 24
Movers
Press releases
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
22 Mar 24
Press Releases
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
13 Mar 24
Press Releases
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
12 Mar 24
Press Releases
Tonix Pharmaceuticals Pioneering in the shifting landscape of the Dynamic CNS Therapeutics Market
13 Feb 24
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
12 Feb 24
Press Releases
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
5 Feb 24
Press Releases